Sotera Health Company

Valuation Analysis

About the Company

Sotera Health Company provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment offers outsourced terminal sterilization and irradiation services using gamma irradiation, ethylene oxide processing, and electron beam irradiation technologies for medical devices, pharmaceutical, and food safety and advanced applications markets. The Nordion segment provides Cobalt-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. It also offers gamma irradiation system

Sotera Health Company Stock at a Glance

Sotera Health Company (SHC) is currently trading at $16.19 with a market capitalization of $4.6B. The trailing P/E ratio stands at 39.49x, with a forward P/E of 15.23x. The 52-week range spans from $10.79 to $19.85; the current price is 18.4% below the yearly high. Year-over-year revenue growth stands at +10.0%. The net profit margin stands at 9.91%.

💰 Dividend

Sotera Health Company currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

9 analysts rate Sotera Health Company (SHC) on consensus: Buy. The average price target is $20.11, implying +24.22% from the current price. Analyst price targets range from $16.00 to $24.00.

Sotera Health Company: The Investment Case in Detail

Sotera Health Company (SHC) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Revenue is growing at a healthy 10% pace year-over-year, suggesting the business model continues to find new customers and pricing power. The combination of a 55.26% gross margin and 31.26% operating margin shows the business converts revenue into profit efficiently — a hallmark of competitive moat. Wall Street consensus sits at Buy with an average price target implying roughly 24.22% upside from current levels — analyst sentiment is firmly constructive.

The Bear Case

The debt-to-equity ratio of 364.72% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valuation in Context

The PEG ratio at 1.31 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.

What to Watch Next

• The forward P/E of 15.23x is meaningfully below the trailing 39.49x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 24.22% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

The data points to above-average price swings, elevated short interest (7.63%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy Sotera Health Company?

Compare top-rated brokers — low fees, trusted providers, fully regulated.